Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Bio TherapeuticsROCO:6892 -2.78%29 Debt-to-Equity is 0.37 as of Jun. 2025, which is 5% below its 10-year median of 0.39. GuruFocus rates ROCO:6892 with a GF Score™ of 29/100 and a GF Value™ of NT$14.64 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 964 Biotechnology companies, Taiwan Bio Therapeutics ranks worse than 69.29% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Taiwan Bio Therapeutics's Debt-to-Equity or its related term are showing as below:
ROCO:6892'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.39 Max: 1.14
Current: 0.38
During the past 6 years, the highest Debt-to-Equity Ratio of Taiwan Bio Therapeutics was 1.14. The lowest was 0.03. And the median was 0.39.
ROCO:6892's Debt-to-Equity is ranked worse than 69.29% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs ROCO:6892: 0.38
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Taiwan Bio Therapeutics Debt-to-Equity Related Terms
Taiwan Bio Therapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6892 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Taiwan Bio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Bio Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Taiwan Bio Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Bio Therapeutics (ROCO:6892) has a Debt-to-Equity of 0.37 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taiwan Bio Therapeutics and its competitors. This is near median its historical median of 0.39. Over the past decade, Taiwan Bio Therapeutics' Debt-to-Equity has ranged from 0.03 to 1.14. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #668 out of 964 companies in the Biotechnology industry, placing it in the top 69.3%.
Is Taiwan Bio Therapeutics' Debt-to-Equity too high?
Taiwan Bio Therapeutics' current Debt-to-Equity of 0.37 is near median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.14. The Biotechnology industry median Debt-to-Equity is 0.16. Taiwan Bio Therapeutics' value of 0.37 is 138.7% above this industry median. Based on the distribution chart, Taiwan Bio Therapeutics ranks #668 out of 964 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Bio Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #668 out of 964 companies for Debt-to-Equity. This places Taiwan Bio Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Taiwan Bio Therapeutics' value of 0.37 is 138.7% above this benchmark. Historically, Taiwan Bio Therapeutics' own Debt-to-Equity has ranged from 0.03 to 1.14 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.16, Taiwan Bio Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Bio Therapeutics's current Debt-to-Equity of 0.37 is 138.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taiwan Bio Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Bio Therapeutics's current Debt-to-Equity is 0.37, which is near median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.64, compared to a current price of NT$26.20 — trading 79% above its estimated fair value. The current Debt-to-Equity is 0.37, which is near median its 10-year median of 0.39 and 138.7% above the Biotechnology industry median of 0.16. Taiwan Bio Therapeutics' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Debt-to-Equity is 0.37 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$26.20 is trading 79% above its estimated GF Value™ of NT$14.64.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
Debt-to-Equity: 0.37 (near median its 10-year median of 0.39)
GF Value™: NT$14.64 vs. price of NT$26.20 (79% above fair value)
Industry Position: 138.7% above the Biotechnology median (#668 of 964)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
29GF Score
Get the complete analysis for ROCO:6892
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
